SCHEMBL2887016

SCHEMBL2887016

Cc1ccc(C2=CC3CCC(C2)N3C)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.59
SLC6A3 Q01959 6/20 0.59
SLC6A2 P23975 5/20 0.59
HTR6 P50406 1/20 0.49
HTR1A P08908 1/20 0.37
ALDH1A1 P00352 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887015 1.00 SLC6A4 (0.59) SLC6A4SLC6A3SLC6A2HTR6HTR1A
Hydrochloric Acid SCHEMBL2889969 0.99 SLC6A4 (0.58) SLC6A4SLC6A3SLC6A2HTR6HTR1A
SCHEMBL2890215 0.89 SLC6A4 (0.59) SLC6A4SLC6A3SLC6A2HTR6HTR1A
SCHEMBL2890213 0.89 SLC6A4 (0.59) SLC6A4SLC6A3SLC6A2HTR6HTR1A
SCHEMBL1021870 0.89 SLC6A4 (0.62) SLC6A4SLC6A3SLC6A2HTR6HTR1A
SCHEMBL1021872 0.89 SLC6A4 (0.62) SLC6A4SLC6A3SLC6A2HTR6HTR1A
Hydrochloric Acid SCHEMBL2886114 0.88 SLC6A4 (0.58) SLC6A4SLC6A3SLC6A2HTR6HTR1A
Hydrochloric Acid SCHEMBL1023143 0.87 SLC6A4 (0.60) SLC6A4SLC6A3SLC6A2HTR6HTR1A
SCHEMBL2892573 0.87 SLC6A2 (0.63) SLC6A4SLC6A3SLC6A2HTR6
SCHEMBL2892576 0.87 SLC6A2 (0.63) SLC6A4SLC6A3SLC6A2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286193-A1 Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2010-11-11 US claimed
EP-1937261-B1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-03-03 EP claimed
EP-1937261-A1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-07-02 EP claimed
WO-2007025978-A1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-03-08 WO claimed
US-20100286193-A1 Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2010-11-11 US disclosed
EP-1937261-B1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-03-03 EP disclosed
EP-1937261-A1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-07-02 EP disclosed
WO-2007025978-A1 NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286193-A1 Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC6A2, SLC18A2, SLC18A3 SLC6A4 6/4885SLC6A3 5/4885SLC6A2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.